RecruitingPhase 3NCT06084936
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Obinutuzumab(drug)
- Enrollment
- 182 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Alta Bates Summit Medical Center, Berkeley, California, United States
- City of Hope Cancer Center, Duarte, California, United States
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California, United States
- Yale Cancer Center, New Haven, Connecticut, United States
- Georgetown University, Washington D.C., District of Columbia, United States
- University of Miami, Coral Gables, Florida, United States
- Indiana University, Indianapolis, Indiana, United States
- University of Michigan Health System, Ann Arbor, Michigan, United States
- St. Luke's Hospital, Chesterfield, Missouri, United States
- Renown Regional Medical Center, Reno, Nevada, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- University of Rochester, Rochester, New York, United States
- Medical University of S. Carolina, Charleston, South Carolina, United States
- Avera Cancer Institute, Sioux Falls, South Dakota, United States
- Renovatio Clinical - El Paso, El Paso, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06084936 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06675123Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGPHASE2NCT07082686A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)Beijing InnoCare Pharma Tech Co., Ltd.
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT07199296Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRuijin Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University